Pyxis Oncology (PYXS) Current Assets (2020 - 2026)

Pyxis Oncology (PYXS) has reported Current Assets for 7 consecutive years, with $36.7 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Current Assets fell 63.25% year-over-year to $36.7 million in Q2 2026; TTM through Jun 2026 was $36.7 million, a 63.25% decrease from a year earlier, with the FY2025 full-year figure at $72.1 million, down 45.56% from the prior year.
• Current Assets was $36.7 million for Q2 2026 at Pyxis Oncology, down from $72.1 million in the prior quarter.
• Over five years, Current Assets peaked at $251.3 million in Q1 2022 and troughed at $36.7 million in Q2 2026.
• A 5-year average of $144.4 million and a median of $148.9 million in 2024 frame the typical range for Current Assets.
• Across the five-year window, Current Assets surged 50.97% in 2022 and sank 63.25% in 2026, its largest moves.
• Over 5 years, Current Assets stood at $186.6 million in 2022, then slumped by 33.23% to $124.6 million in 2023, then gained by 6.29% to $132.4 million in 2024, then sank by 45.56% to $72.1 million in 2025, then plunged by 49.05% to $36.7 million in 2026.
• The last three Current Assets figures came in at $36.7 million (Q2 2026), $72.1 million (Q4 2025), and $83.1 million (Q3 2025), per Business Quant data.